Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BioNTech SE ( (BNTX) ) has provided an update.
On May 5, 2026, BioNTech reported first-quarter 2026 revenues of €118.1 million, down from €182.8 million a year earlier, reflecting lower COVID-19 vaccine sales and resulting in a net loss of €531.9 million. The company reaffirmed its 2026 revenue guidance of €2.0 billion to €2.3 billion and highlighted a strong liquidity position with €16.8 billion in cash, cash equivalents and security investments as of March 31, 2026.
Management said spending increases were driven by expansion of its immuno-oncology and antibody-drug conjugate pipeline, including key assets pumitamig and gotistobart, and the integration of BioNTech China and CureVac acquired in 2025. BioNTech outlined a catalyst-heavy year with multiple late-stage oncology data readouts, ongoing COVID-19 variant-adapted vaccine preparations, manufacturing footprint consolidation to boost efficiency, and a planned ADS share repurchase program of up to $1.0 billion, signaling confidence in its long-term oncology-focused strategy despite near-term losses.
The most recent analyst rating on (BNTX) stock is a Buy with a $130.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
Spark’s Take on BNTX Stock
According to Spark, TipRanks’ AI Analyst, BNTX is a Neutral.
The score is held back primarily by deteriorated profitability and bearish technicals (price below major moving averages with negative MACD). Offsetting factors include strong solvency and liquidity with very low leverage, plus a generally constructive earnings update around pipeline progress and strategic de-risking, though near-term guidance points to lower revenues and higher spend.
To see Spark’s full report on BNTX stock, click here.
More about BioNTech SE
BioNTech SE is a German biopharmaceutical company specializing in immunotherapies, notably mRNA-based vaccines and oncology treatments. Having gained global prominence with its COVID-19 vaccine developed with Pfizer, the company is now focused on building a diversified oncology franchise, including immuno-oncology and antibody-drug conjugate programs, targeting global cancer markets.
Average Trading Volume: 1,107,086
Technical Sentiment Signal: Sell
Current Market Cap: $24.97B
Learn more about BNTX stock on TipRanks’ Stock Analysis page.